44 Result(s)
within
Muthiah Vaduganathan
-
Article
Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease
Balancing the safety and efficacy of antithrombotic agents in patients with gastrointestinal disorders is challenging because of the potential for interference with the absorption of antithrombotic drugs and f...
-
Article
Open AccessAuthor Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
-
Article
Open AccessDapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
With modern treatments for heart failure with reduced ejection fraction (EF), indicative of impaired cardiac systolic function, patients may exhibit an increase in EF. Limited data are available regarding the ...
-
Article
Polypharmacy in Older Heart Failure Patients: a Multidisciplinary Approach
We provide a review of considerations when applying principles of optimal pharmacotherapy to older adults with heart failure (HF), an analysis on the pivotal clinical trials focusing on applicability to older ...
-
Article
Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have evident cardiovascular benefits in patients with type 2 diabetes with or at high risk for atherosclerotic cardiovascular disease, heart failure with reduc...
-
Article
Contemporary Trends in the Use of and Expenditures on Digoxin in the United States
Digoxin is indicated for the management of heart failure with reduced ejection fraction and atrial fibrillation. Despite stronger guideline recommendations for other pharmacologic and device therapies, digoxin...
-
Article
Open AccessDapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a range of morbidity and mortality outcomes in patients with heart failure regardless of ejection fraction is unknown. A p...
-
Article
Open AccessEffects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials
Compared with enalapril, sacubitril/valsartan lowered HbA1c and reduced new insulin therapy in patients with heart failure with reduced ejection fraction (HFrEF) and diabetes in the PARADIGM-HF trial. We sough...
-
Article
Implementation of Cardiometabolic Centers and Training Programs
Type 2 diabetes is frequently accompanied by obesity, nonalcoholic fatty liver disease, chronic kidney disease, and cardiovascular disease, which collectively contribute to the high burden of cardiometabolic d...
-
Chapter and Conference Paper
Ambient Fine Particulate Matter and COVID-19 in India
We examine the correlation between COVID-19 case activity and air pollution in two cities of Delhi and Mumbai in India. Data regarding air quality index (AQI) of PM2.5 and PM10 from Delhi and Mumbai were colle...
-
Article
Editorial Expression of Concern: Water and sodium in heart failure: a spotlight on congestion
-
Article
Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes
Type 2 diabetes (T2D) is associated with an increased risk of heart failure (HF), with diabetic cardiomyopathy (DbCM) referring to abnormal heart structure in the absence of other driving cardiac factors such ...
-
Article
Development and validation of optimal phenomap** methods to estimate long-term atherosclerotic cardiovascular disease risk in patients with type 2 diabetes
Type 2 diabetes is a heterogeneous disease process with variable trajectories of CVD risk. We aimed to evaluate four phenomap** strategies and their ability to stratify CVD risk in individuals with type 2 di...
-
Article
Open AccessBias in natriuretic peptide-guided heart failure trials: time to improve guideline adherence using alternative approaches
Treatment of patients with heart failure with reduced ejection fraction (HFrEF) with currently available therapies reduces morbidity and mortality. However, implementation of these therapies is a problem with ...
-
Article
What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?
We highlight the unique properties of the sodium-glucose cotransporter-2 (SGLT-2 inhibitors) which may lend favorably to their efficient integration in the background of other heart failure (HF) therapies. We ...
-
Article
Reappraisal of the safety and effectiveness of Impella pumps
In the decade after the introduction of Impella heart pumps, their use has rapidly increased. However, to date, clinical trial data have not conclusively supported their superiority over other contemporary sup...
-
Article
Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in individuals with type 2 diabetes (T2D). Recent cardiovascular outcome trials (CVOTs) have established sodium-glucose co-transport...
-
Article
SGLT-2 inhibitors in heart failure: a new therapeutic avenue
Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, reduced the risk of cardiovascular death or heart failure events in 4,744 patients with chronic heart failure with reduced ejection fraction.
-
Article
Electrocardiography and left ventricular function: looking beyond hypertrophy
-
Article
Expanded algorithm for managing patients with acute decompensated heart failure
Heart failure is a complex disease process, the manifestation of various cardiac and noncardiac abnormalities. General treatment approaches for heart failure have remained the same over the past decades despit...
